Ocuphire Pharma Investor Day Presentation Deck
P
106
Summary of Nyxol and Nyxol+LDP Presbyopia Program
慢
Г
J
Nyxol as a single drop is differentiated as a new MOA class working on the iris dilator
muscles; Nyxol with LDP as adjunct therapy uniquely offers pupil 'tunability' depending on
patient lifestyle
In VEGA-1 trial:
Nyxol+LDP met its primary efficacy endpoint ≥ 15 letter near visual acuity gain.
Nyxol as a single drop met efficacy endpoints at 12 hours and 18 hours
Consistent with prior trials across other indications, Nyxol, dosed alone or with LDP, has
demonstrated favorable safety and tolerability
VEGA Phase 3 program planned for Nyxol and Nyxol+LDP for the treatment of presbyopia to
initiate mid-2022
Potential NDA submissions for presbyopia in 2023
Nyxol as a single drop
Nyxol with LDP as adjunct therapy
Presbyopia drops projected to be one of the largest $10+B new segments in Ophthalmology
Ocuphire
PHARMAView entire presentation